by milena henderson | Dec 11, 2025 | Newsletters
As we approach the end of the year, we would like to take a moment to reflect on what has been a significant and impactful 2025 for Pharmalys. This year marked an important milestone with Pharmalys taking over operations of the GCLP accreditation scheme from Tim...
by milena henderson | Dec 1, 2025 | Newsletters
Highlights from the final Pharmalys Voice Meeting of 2025 On September 25, 2025, Pharmalys held its third and final Pharmalys Voice meeting of the year, bringing together colleagues from across the company in a fun and interactive virtual gathering. The meeting...
by milena henderson | Dec 1, 2025 | Newsletters
Pharmacoequity: Improving Representation in Medicine and Fairness in Care Access to safe and effective medicines is a cornerstone of modern healthcare. Yet, not everyone enjoys equal benefit from the advancements in pharmaceutical research and innovation....
by milena henderson | Jul 15, 2025 | Newsletters
Female Genital Mutilation/Cutting: Understanding the Ongoing Global Crisis Female genital mutilation (FGM) is defined by the World Health Organization (WHO) as ‘all procedures which intentionally alter or damage the external female genitalia organs for non-medical...
by milena henderson | Jun 2, 2025 | Newsletters
Pharmalys is pleased to announce that, effective from 2025, we have taken on the full management of the Good Clinical Laboratory Practice (GCLP) Accreditation Scheme, which we have co-managed with Tim Stiles of Qualogy 2002 Ltd for the past two years. This marks an...
by milena henderson | Jun 2, 2025 | Newsletters
Senegal Leads the Way: First Francophone African Country to Achieve WHO Maturity Level 3! We are thrilled to celebrate a significant achievement in global health and pharmaceutical innovation: Senegal has become the first Francophone country – and seventh country...
